Cardiac Biomarkers Market To Grow Fastest in APAC
The cardiac biomarkers industry is projected to rise at a rate of 10.5%, to capture $20,718.8 million revenue in 2030.
pnsintel
In 2021, total size of the cardiac biomarkers market was USD 8,459.6 million and it will generate a revenue of USD 20,718.8 million by 2030, pushing at a growth rate of 10.5%.
Troponin had the major share of revenue of 35% in the recent past, and it will grow at a healthy rate in the years to come. It has a lot to do with the unexpected specificity, and capacity of their protein complex for supporting recognizing cardiac issues, including ACS, with accuracy.
Moreover, the increasing cases of myocardial infraction will boost the industry, as troponin is a prevalent tool for detecting this condition.
North America is the highest revenue contributor in the industry, with a revenue share of more than 35% in the past. This has a lot to do with the increasing use of biomarkers for precision medicine, different strategies for growth adopted by market players, and the increasing acceptance of biomarkers for the detection of cardiac ailments.
APAC will have the fastest growth at a rate of 11%. The reasons for this growth are developing healthcare infra, numerous government schemes for the healthcare sector, increasing prevalence of cardiac diseases etc.
It is because of the increasing incidence for the acute coronary syndrome, the demand for the cardiac biomarkers is on the rise globally.
